FMP
PNK
15.64 USD
1.3 (8.31%)
Mr. Punit S. Dhillon B.A., BA
Healthcare
Biotechnology
https://skyebioscience.com
PNK
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
0001516551
US83086J2006
83086J101
11250 El Camino Real
858 410 0266
US
11
Nov 26, 2014